# Top 10 population extracts from nccp-lung-guideline-full_cleaned.json

=== Ranked Population 1 (Extract #17, Population) — Score: 14 ===
e survival was longer
in the afatinib group (3.3 months, 95% CI 2.79–4.40)
than it was in the placebo group (1.1 months, 0.95–
1.68; HR 0.38, 95% CI 0.31–0.48; p<0.0001).
| A National Clinical
Patient population
Patients with non-s
NSCLC that had pro
during or after plati
based doublet chem
Patient population
Patients with advan
squamous-cell NSC
have disease progre
during or after first
chemotherapy.
Patient population
Patients with previo
treated, PD-L1-posi
advanced NSCLC.
The following sing
positive tumours:
Patient population
Patients with locally
or metastatic ALK-p
lung cancer who ha
one prior pl

=== Ranked Population 2 (Extract #18, Population) — Score: 14 ===
months, 0.95–
1.68; HR 0.38, 95% CI 0.31–0.48; p<0.0001).
| A National Clinical
Patient population
Patients with non-s
NSCLC that had pro
during or after plati
based doublet chem
Patient population
Patients with advan
squamous-cell NSC
have disease progre
during or after first
chemotherapy.
Patient population
Patients with previo
treated, PD-L1-posi
advanced NSCLC.
The following sing
positive tumours:
Patient population
Patients with locally
or metastatic ALK-p
lung cancer who ha
one prior platinum-
regimen.
l Guid
n:
squam
ogress
tinum-
mothe
n:
nced
CLC wh
ession
t-line
n:
ously
itive,
gle ag
n:
y adv

=== Ranked Population 3 (Extract #34, Population) — Score: 14 ===
and non-co
Population:
Intervention:
Comparison:
Outcome:
Clinical question 2.2.2
In patients with periphe
cancer?
- Percutaneous fine ne
- Guided bronchoscop
- Video assisted thora
Population:
Intervention:
Comparison:
Outcome:
Clinical question 2.2.3
In NSCLC patients with e
ablative techniques?
Population:
Intervention:
Comparison:
Outcome:
Clinical question 2.2.4
For patients with NSCLC
a role for imaging surve
Population:
Intervention:
Comparison:
Outcome:
deline | Diagnosis, staging and treatment of
nical Questions in PICO format
ancer (NSCLC) patients with mediastinal and hilar adenopathy what i

=== Ranked Population 4 (Extract #37, Population) — Score: 14 ===
mical shift MRI, non-c
Population: Patients with lung cancer with metastati
masses
Intervention: Chemical shift MRI, non-contrast CT, PE
Comparison: -
Outcome: Detection of metastatic spread to indet
Clinical question 2.2.6
For patients with NSCLC which of the following tests is most accura
PET-CT?
Population: Patients with NSCLC with brain metasta
Intervention: MRI, CT, PET-CT
Comparison: -
Outcome: Detection of brain metastases
Clinical question 2.2.7
For patients with NSCLC which of the following tests is most accura
bone scan, CT, MRI, PET-CT?
Population: For patients with NSCLC with suspected
Inter

=== Ranked Population 5 (Extract #38, Population) — Score: 14 ===
of the following tests is most accura
PET-CT?
Population: Patients with NSCLC with brain metasta
Intervention: MRI, CT, PET-CT
Comparison: -
Outcome: Detection of brain metastases
Clinical question 2.2.7
For patients with NSCLC which of the following tests is most accura
bone scan, CT, MRI, PET-CT?
Population: For patients with NSCLC with suspected
Intervention: Isotope bone scan, CT, MRI, PET-CT
Comparison: –
Outcome: Detection of bone metastases
Clinical question 2.2.8
In patients with limited-stage SCLC on diagnostic CT, does PET-CT ch
Population: Patients with limited-stage SCLC on diag
Intervention

=== Ranked Population 6 (Extract #399, Patients) — Score: 14 ===
ties, or patient preference. Seven patients (35%) treated surgically had tumours that
were ipsilateral to their primary tumour, and eight (40%) had metachronous metastases. Five-year overall
survival was 34% for patients treated operatively and 0% for patients treated nonoperatively p=0.002).
Among patients treated with adrenalectomy, patients with ipsilateral metastases had a 5-year survival of
83% compared with 0% for patients with contralateral metastases (p=0.003). Patients without mediastinal
nodal disease had a 5-year survival of 52% compared with 0% for patients with mediastinal nodal disease
(

=== Ranked Population 7 (Extract #400, Patients) — Score: 14 ===
tients (35%) treated surgically had tumours that
were ipsilateral to their primary tumour, and eight (40%) had metachronous metastases. Five-year overall
survival was 34% for patients treated operatively and 0% for patients treated nonoperatively p=0.002).
Among patients treated with adrenalectomy, patients with ipsilateral metastases had a 5-year survival of
83% compared with 0% for patients with contralateral metastases (p=0.003). Patients without mediastinal
nodal disease had a 5-year survival of 52% compared with 0% for patients with mediastinal nodal disease
(p=0.008). Survival of patients who un

=== Ranked Population 8 (Extract #401, Patients) — Score: 14 ===
ur, and eight (40%) had metachronous metastases. Five-year overall
survival was 34% for patients treated operatively and 0% for patients treated nonoperatively p=0.002).
Among patients treated with adrenalectomy, patients with ipsilateral metastases had a 5-year survival of
83% compared with 0% for patients with contralateral metastases (p=0.003). Patients without mediastinal
nodal disease had a 5-year survival of 52% compared with 0% for patients with mediastinal nodal disease
(p=0.008). Survival of patients who underwent adrenalectomy for synchronous and metachronous adrenal
metastases was not signi

=== Ranked Population 9 (Extract #402, Patients) — Score: 14 ===
ive-year overall
survival was 34% for patients treated operatively and 0% for patients treated nonoperatively p=0.002).
Among patients treated with adrenalectomy, patients with ipsilateral metastases had a 5-year survival of
83% compared with 0% for patients with contralateral metastases (p=0.003). Patients without mediastinal
nodal disease had a 5-year survival of 52% compared with 0% for patients with mediastinal nodal disease
(p=0.008). Survival of patients who underwent adrenalectomy for synchronous and metachronous adrenal
metastases was not significantly different (p=0.81). Surgical resection of

=== Ranked Population 10 (Extract #515, Patients) — Score: 14 ===
was longer
in the afatinib group (3.3 months, 95% CI 2.79–4.40)
than it was in the placebo group (1.1 months, 0.95–
1.68; HR 0.38, 95% CI 0.31–0.48; p<0.0001).
| A National Clinical
Patient population
Patients with non-s
NSCLC that had pro
during or after plati
based doublet chem
Patient population
Patients with advan
squamous-cell NSC
have disease progre
during or after first
chemotherapy.
Patient population
Patients with previo
treated, PD-L1-posi
advanced NSCLC.
The following sing
positive tumours:
Patient population
Patients with locally
or metastatic ALK-p
lung cancer who ha
one prior platinum-
r

